These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22532524)

  • 1. A native chemical ligation approach for combinatorial assembly of affibody molecules.
    Lindgren J; Ekblad C; Abrahmsén L; Eriksson Karlström A
    Chembiochem; 2012 May; 13(7):1024-31. PubMed ID: 22532524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and characterization of Affibody ligands to the transcription factor c-Jun.
    Lundberg E; Brismar H; Gräslund T
    Biotechnol Appl Biochem; 2009 Jan; 52(Pt 1):17-27. PubMed ID: 18260830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold.
    Nygren PA
    FEBS J; 2008 Jun; 275(11):2668-76. PubMed ID: 18435759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affibody protein capture microarrays: synthesis and evaluation of random and directed immobilization of affibody molecules.
    Renberg B; Shiroyama I; Engfeldt T; Nygren PK; Karlström AE
    Anal Biochem; 2005 Jun; 341(2):334-43. PubMed ID: 15907880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated Fmoc-based solid-phase synthesis of peptide thioesters with self-purification effect and application in the construction of immobilized SH3 domains.
    Mende F; Beisswenger M; Seitz O
    J Am Chem Soc; 2010 Aug; 132(32):11110-8. PubMed ID: 20662535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of an optimized scaffold for affibody molecules.
    Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
    J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications.
    Löfblom J; Feldwisch J; Tolmachev V; Carlsson J; Ståhl S; Frejd FY
    FEBS Lett; 2010 Jun; 584(12):2670-80. PubMed ID: 20388508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
    Wållberg H; Löfdahl PK; Tschapalda K; Uhlén M; Tolmachev V; Nygren PK; Ståhl S
    Protein Expr Purif; 2011 Mar; 76(1):127-35. PubMed ID: 21029777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering of affibody molecules for therapy and diagnostics.
    Feldwisch J; Tolmachev V
    Methods Mol Biol; 2012; 899():103-26. PubMed ID: 22735949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of protected peptidyl thioester intermediates for native chemical ligation by Nalpha-9-fluorenylmethoxycarbonyl (Fmoc) chemistry: considerations of side-chain and backbone anchoring strategies, and compatible protection for N-terminal cysteine.
    Gross CM; Lelièvre D; Woodward CK; Barany G
    J Pept Res; 2005 Mar; 65(3):395-410. PubMed ID: 15787970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection and characterization of Affibody ligands binding to Alzheimer amyloid beta peptides.
    Grönwall C; Jonsson A; Lindström S; Gunneriusson E; Ståhl S; Herne N
    J Biotechnol; 2007 Jan; 128(1):162-83. PubMed ID: 17088007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo.
    Lindborg M; Cortez E; Höidén-Guthenberg I; Gunneriusson E; von Hage E; Syud F; Morrison M; Abrahmsén L; Herne N; Pietras K; Frejd FY
    J Mol Biol; 2011 Mar; 407(2):298-315. PubMed ID: 21277312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay.
    Löfdahl PA; Nord O; Janzon L; Nygren PA
    N Biotechnol; 2009 Nov; 26(5):251-9. PubMed ID: 19576305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for molecular recognition in an affibody:affibody complex.
    Lendel C; Dogan J; Härd T
    J Mol Biol; 2006 Jun; 359(5):1293-304. PubMed ID: 16750222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide affinity chromatography media that bind N(pro) fusion proteins under chaotropic conditions.
    Hahn R; Seifert M; Greinstetter S; Kanatschnig B; Berger E; Kaar W; Jungbauer A
    J Chromatogr A; 2010 Oct; 1217(40):6203-13. PubMed ID: 20800233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A designed branched three-helix bundle protein dimer.
    Dolphin GT
    J Am Chem Soc; 2006 Jun; 128(22):7287-90. PubMed ID: 16734482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptides as protein binding site mimetics.
    Eichler J
    Curr Opin Chem Biol; 2008 Dec; 12(6):707-13. PubMed ID: 18935974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
    Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
    Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of tumour-necrosis-factor-alpha-specific affibody molecules capable of blocking receptor binding in vitro.
    Jonsson A; Wållberg H; Herne N; Ståhl S; Frejd FY
    Biotechnol Appl Biochem; 2009 Aug; 54(2):93-103. PubMed ID: 19545237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-specific protein immobilization by Staudinger ligation.
    Soellner MB; Dickson KA; Nilsson BL; Raines RT
    J Am Chem Soc; 2003 Oct; 125(39):11790-1. PubMed ID: 14505380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.